정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2130 | Withdrawn | Azithromycin Plus Hydroxychloroquine for COVID-19 Infection | Respiratory Tract Infection Viral | Drug: Azithromycin plus hydroxychloroquine | Phase 3 | Iterum Therapeutics, International Limited, Waterbury Hospital | INDUSTRY | 0 | All | 18 Years | Waterbury Hospial, Waterbury, Connecticut, United States |
| 2129 | Not yet recruiting | Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit | COVID-19 Pneumonia | Combination Product: Azithromycin with amoxicillin/clavulanate Drug: amoxicillin/clavulanate |
Phase 3 | Nantes University Hospital | OTHER | 104 | All | 18 Years ~ 99 Years | Chu Angers, Angers, France CHD Vendee, La Roche-sur-Yon, France CHU Poitiers, Poitiers, France |
| 2128 | Recruiting | Azithromycin-Prevention in Labor Use Study (A-PLUS) | Postpartum Sepsis | Drug: Azithromycin Drug: Placebo |
Phase 3 | NICHD Global Network for Women's and Children's Health, University of Alabama at Birmingham, University Teaching Hospital, Lusaka, Zambia, University of North Carolina, Chapel Hill, Kinshasa School of Public Health, University of Colorado, Denver, Institute of Nutrition of Central America and Panama, University of Virginia, International Centre for Diarrhoeal Disease Research, Bangladesh, Thomas Jefferson University, Columbia University, Aga Khan University, Boston University, Lata Medical Research Foundation, Nagpur, Indiana University School of Medicine, Moi Univeristy, RTI International, Bill and Melinda Gates Foundation, KLE University's Jawaharlal Nehru Medical College | NETWORK | 34000 | Female | 18 Years ~ 45 Years | ICDDRB, Dhaka, Bangladesh Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the Institute for Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala Jawaharlal Nehru Medical College, Belagavi, India Lata Medical Research Foundation, Nagpur, India Moi University School of Medicine, Eldoret, Kenya The Aga Khan University, Karachi, Pakistan University Teaching Hospital, Lusaka, Zambia |
| 2127 | Completed | Bacillus Calmette-guerin Vaccination to Prevent COVID-19 | Chronic Obstructive Pulmonary Disease | Biological: BCG vaccine Biological: Placebo |
Phase 4 | Hellenic Institute for the Study of Sepsis | OTHER | 301 | All | 50 Years | General Hospital of Argolida - Nafplion Unit, Nafplio, Argos, Greece 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece Department of Therapeutics, Alexandra General Hospital, Athens, Greece 1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece 2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece 3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece 4th Department of Internal Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece Department of Pulmonary Medicine- General Hospital of Kerkyra, Corfu, Greece 1st Department of Internal Medicine, General University Hospital of Ioannina, Ioannina, Greece Department of Internal Medicine, General Hospital of Karditsa, Karditsa, Greece General Hospital of Korinthos, Korinthos, Greece Department of Internal Medicine, Patras University Hospital, Patras, Greece General Hospital of Ptolemaida MPODOSAKEIO, Ptolema?da, Greece 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece General Hospital of Imathia - Veria Unit, Veria, Greece |
| 2126 | Completed | BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) | Covid19 | Drug: Bardoxolone Methyl Drug: Placebo |
Phase 2 | NYU Langone Health, Reata Pharmaceuticals, Inc. | OTHER | 40 | All | 18 Years | HSHS St. John's Hospital (Prairie Education and Research Cooperative), Springfield, Illinois, United States SIU School of Medicine, Springfield, Illinois, United States NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States Coney Island Hospital, Brooklyn, New York, United States Elmhurst Hospital Center, Elmhurst, New York, United States NYU Winthrop Hospital, Mineola, New York, United States NYU Bellevue Hospital Center, New York, New York, United States NYU Langone Health, New York, New York, United States |
| 2125 | Not yet recruiting | Baricitinib Compared to Standard Therapy in Patients With COVID-19 | SARS Pneumonia | Drug: Baricitinib Oral Tablet | Phase 2 | Azienda Ospedaliero, Universitaria Pisana | OTHER | 126 | All | 18 Years | Azienda Ospedaliero Universitaria Pisana, Pisa, Italy |
| 2124 | Not yet recruiting | Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial | Corona Virus Infection | Drug: Baricitinib | Phase 2 | IRCCS Policlinico S. Matteo | OTHER | 13 | All | 18 Years ~ 74 Years |
